• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Blood >Clinical Trials and Observations: Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
【2h】

Clinical Trials and Observations: Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

机译：临床试验和观察：急性髓样白血病完全缓解的患者接种源自WT1癌蛋白的合成类似物肽可诱导T细胞反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A pilot study was undertaken to assess the safety, activity, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acute myeloid leukemia in complete remission but with molecular evidence of WT1 transcript. Patients received 6 vaccinations with 4 WT1 peptides (200 μg each) plus immune adjuvants over 12 weeks. Immune responses were evaluated by delayed-type hypersensitivity, CD4+ T-cell proliferation, CD3+ T-cell interferon-γ release, and WT1 peptide tetramer staining. Of the 9 evaluable patients, 7 completed 6 vaccinations and WT1-specific T-cell responses were noted in 7 of 8 patients. Three patients who were HLA-A0201-positive showed significant increase in interferon-γ–secreting cells and frequency of WT1 tetramer-positive CD8+ T cells. Three patients developed a delayed hypersensitivity reaction after vaccination. Definite related toxicities were minimal. With a mean follow-up of 30 plus or minus 8 months after diagnosis, median disease-free survival has not been reached. These preliminary data suggest that this polyvalent WT1 peptide vaccine can be administered safely to patients with a resulting immune response. Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia. This study was registered at as #.
机译：进行了一项初步研究，以评估完全缓解但有WT1转录物分子证据的急性髓样白血病患者中多价Wilms肿瘤基因1（WT1）肽疫苗的安全性，活性和免疫原性。患者在12周内接受了4种WT1肽（每种200μg）加免疫佐剂的6次疫苗接种。通过迟发型超敏反应，CD4 + T细胞增殖，CD3 + T细胞干扰素-γ释放和WT1肽四聚体染色评估免疫应答。在9位可评估的患者中，有8位患者中有7位完成了6次疫苗接种，并且有WT1特异性T细胞应答。 HLA-A0201阳性的三例患者显示干扰素-γ分泌细胞和WT1四聚体阳性CD8 + T细胞的频率显着增加。接种疫苗后，三名患者出现迟发性超敏反应。明确的相关毒性很小。诊断后平均随访30个月或以下8个月，未达到中位无病生存期。这些初步数据表明，这种多价WT1肽疫苗可以安全地施用于产生免疫反应的患者。需要进一步的研究来确立疫苗接种作为急性髓细胞白血病可行的缓解后治疗的作用。该研究的注册号为＃。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号